Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Publication

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

Journal Paper/Review - Nov 23, 2015

Geyer Holly L, Scherber Robyn, Kosiorek Heidi, Dueck Amylou C, Kiladjian Jean-Jacques, Xiao Zhijian, Slot Stefanie, Zweegman Sonja, Sackmann Federico, Fuentes Ana Kerguelen, Hernández-Maraver Dolores, Döhner Konstanze, Harrison Claire N, Radia Deepti, Muxi Pablo, Besses Carlos, Cervantes Francisco, Johansson Peter L, Andreasson Bjorn, Rambaldi Alessandro, Barbui Tiziano, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Maldonado Norman, Barosi Giovanni, Ferrari Maria L, Gale Robert Peter, Birgegard Gunnar, Xu Zefeng, Zhang Yue, Sun Xiujuan, Xu Junqing, Zhang Peihong, te Boekhorst Peter A W, Commandeur Suzan, Schouten Harry, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Lehmann Thomas, Senyak Zhenya, Vannucchi Alessandro M, Passamonti Francesco, Samuelsson Jan, Mesa Ruben A

Citation

Geyer H, Scherber R, Kosiorek H, Dueck A, Kiladjian J, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes A, Hernández-Maraver D, Döhner K, Harrison C, Radia D, Muxi P, Besses C, Cervantes F, Johansson P, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Maldonado N, Barosi G, Ferrari M, Gale R, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst P, Commandeur S, Schouten H, Pahl H, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi A, Passamonti F, Samuelsson J, Mesa R. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. J Clin Oncol 2015; 34:151-9.

Type

Journal Paper/Review (English)

Journal

J Clin Oncol 2015; 34

Publication Date

Nov 23, 2015

Issn Electronic

1527-7755

Pages

151-9

Brief description/objective

Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and a heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness of JAK inhibitor therapy in patients with PV patients who have a history of prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, and palpable splenomegaly. We aimed to determine how these features contribute alone and in aggregate to the PV symptom burden.